カテゴリー： QYResearch, 世界

世界の肺動脈高血圧症（PAH）治療薬市場 2019年

【英語タイトル】Global Pulmonary Arterial Hypertension (PAH) Medicine Market Professional Survey Report 2019

QYResearchが出版した調査資料（DATA909X13888）・商品コード：DATA909X13888
・発行会社（調査会社）：QYResearch
・発行日：2019年11月20日（※2024年版があります。お問い合わせください）
・ページ数：107
・レポート言語：英語
・レポート形式：PDF
・納品方法：Eメール（受注後3営業日）
・調査対象地域：グローバル
・産業分野：医薬品・ヘルスケア
◆販売価格オプション（消費税別）
Single User（1名様閲覧用）USD3,500 ⇒換算￥518,000見積依頼/購入/質問フォーム
Multi User（5名様閲覧用）USD5,250 ⇒換算￥777,000見積依頼/購入/質問フォーム
Enterprise License（同一法人内共有可）USD7,000 ⇒換算￥1,036,000見積依頼/購入/質問フォーム
※販売価格オプションの説明
※お支払金額：換算金額（日本円）＋消費税
※納期：即日〜2営業日（3日以上かかる場合は別途表記又はご連絡）
※お支払方法：納品日＋5日以内に請求書を発行・郵送（請求書発行日より2ヶ月以内に銀行振込、振込先：三菱UFJ銀行/H&Iグローバルリサーチ株式会社、支払期限と方法は調整可能）
※本調査レポートは、肺動脈高血圧症（PAH）治療薬の世界市場概要、製造コスト分析、開発・製造工場分析、主要メーカー分析、地域別分析情報、市場規模予測データ、マーケティングチャネル、流通業者リスト、顧客リストなどが含まれています。種類別には、エンドセリン受容体拮抗薬（ERA）、プロスタサイクリンおよびプロスタサイクリンアナログ、ホスホジエステラーゼ5（PDE-5）、可溶性グアニル酸シクラーゼ（SGC）刺激剤に、用途別には、二次性肺高血圧症（SPH）、原発性肺高血圧症（PPH）にセグメント区分し、肺動脈高血圧症（PAH）治療薬の世界市場を分析しました。


・エグゼクティブ・サマリー
・肺動脈高血圧症（PAH）治療薬の世界市場概要
・肺動脈高血圧症（PAH）治療薬の製造コスト構成分析
・肺動脈高血圧症（PAH）治療薬の開発・製造工場分析
・主要メーカーの主な指標（生産能力、売上、価格分析）
・肺動脈高血圧症（PAH）治療薬の地域別分析（生産、売上、主要メーカー、輸出・輸入）
（北米、ヨーロッパ、中国、日本国内、東南アジア、インド）
・肺動脈高血圧症（PAH）治療薬のセグメント分析（種類別）
（エンドセリン受容体拮抗薬（ERA）、プロスタサイクリンおよびプロスタサイクリンアナログ、ホスホジエステラーゼ5（PDE-5）、可溶性グアニル酸シクラーゼ（SGC）刺激剤）
・肺動脈高血圧症（PAH）治療薬のセグメント分析（用途別）
（二次性肺高血圧症（SPH）、原発性肺高血圧症（PPH））
・肺動脈高血圧症（PAH）治療薬の主要メーカー別分析（生産拠点、製品概要、生産・売上実績）
（Actelion Pharmaceuticals、Gilead Sciences、United Therapeutics Corporation、GlaxoSmithKline、Pfizer、Bayer HealthCare、Arena Pharmaceuticals、）
・肺動脈高血圧症（PAH）治療薬の市場規模予測（2019年～2025年）
（北米、ヨーロッパ、中国、日本国内、東南アジア、インド）
・マーケティングチャネル・流通業者・顧客
・市場ダイナミクス（市場動向、機会、成長要因、課題、影響因子）
...
【レポートの概要】

The global Pulmonary Arterial Hypertension (PAH) Medicine market was valued at million US$ in 2018 and will reach million US$ by the end of 2025, growing at a CAGR of during 2019-2025.
This report focuses on Pulmonary Arterial Hypertension (PAH) Medicine volume and value at global level, regional level and company level. From a global perspective, this report represents overall Pulmonary Arterial Hypertension (PAH) Medicine market size by analyzing historical data and future prospect.
Regionally, this report categorizes the production, apparent consumption, export and import of Pulmonary Arterial Hypertension (PAH) Medicine in North America, Europe, China, Japan, Southeast Asia and India.
For each manufacturer covered, this report analyzes their Pulmonary Arterial Hypertension (PAH) Medicine manufacturing sites, capacity, production, ex-factory price, revenue and market share in global market.

The following manufacturers are covered:
Actelion Pharmaceuticals
Gilead Sciences
United Therapeutics Corporation
GlaxoSmithKline
Pfizer
Bayer HealthCare
Arena Pharmaceuticals
…

Segment by Regions
North America
Europe
China
Japan
Southeast Asia
India

Segment by Type
Endothelin Receptor Antagonists (ERA)
Prostacyclin And Prostacyclin Analogs
Phosphodiesterase 5 (PDE-5)
Soluble Guanylate Cyclase (SGC) Stimulators

Segment by Application
Secondary Pulmonary Hypertension (SPH)
Primary Pulmonary Hypertension (PPH)

【レポートの目次】

Table of Contents

Executive Summary
1 Industry Overview of Pulmonary Arterial Hypertension (PAH) Medicine
1.1 Definition of Pulmonary Arterial Hypertension (PAH) Medicine
1.2 Pulmonary Arterial Hypertension (PAH) Medicine Segment by Type
1.2.1 Global Pulmonary Arterial Hypertension (PAH) Medicine Production Growth Rate Comparison by Types (2014-2025)
1.2.2 Endothelin Receptor Antagonists (ERA)
1.2.3 Prostacyclin And Prostacyclin Analogs
1.2.4 Phosphodiesterase 5 (PDE-5)
1.2.5 Soluble Guanylate Cyclase (SGC) Stimulators
1.3 Pulmonary Arterial Hypertension (PAH) Medicine Segment by Applications
1.3.1 Global Pulmonary Arterial Hypertension (PAH) Medicine Consumption Comparison by Applications (2014-2025)
1.3.2 Secondary Pulmonary Hypertension (SPH)
1.3.3 Primary Pulmonary Hypertension (PPH)
1.4 Global Pulmonary Arterial Hypertension (PAH) Medicine Overall Market
1.4.1 Global Pulmonary Arterial Hypertension (PAH) Medicine Revenue (2014-2025)
1.4.2 Global Pulmonary Arterial Hypertension (PAH) Medicine Production (2014-2025)
1.4.3 North America Pulmonary Arterial Hypertension (PAH) Medicine Status and Prospect (2014-2025)
1.4.4 Europe Pulmonary Arterial Hypertension (PAH) Medicine Status and Prospect (2014-2025)
1.4.5 China Pulmonary Arterial Hypertension (PAH) Medicine Status and Prospect (2014-2025)
1.4.6 Japan Pulmonary Arterial Hypertension (PAH) Medicine Status and Prospect (2014-2025)
1.4.7 Southeast Asia Pulmonary Arterial Hypertension (PAH) Medicine Status and Prospect (2014-2025)
1.4.8 India Pulmonary Arterial Hypertension (PAH) Medicine Status and Prospect (2014-2025)

2 Manufacturing Cost Structure Analysis
2.1 Raw Material and Suppliers
2.2 Manufacturing Cost Structure Analysis of Pulmonary Arterial Hypertension (PAH) Medicine
2.3 Manufacturing Process Analysis of Pulmonary Arterial Hypertension (PAH) Medicine
2.4 Industry Chain Structure of Pulmonary Arterial Hypertension (PAH) Medicine

3 Development and Manufacturing Plants Analysis of Pulmonary Arterial Hypertension (PAH) Medicine
3.1 Capacity and Commercial Production Date
3.2 Global Pulmonary Arterial Hypertension (PAH) Medicine Manufacturing Plants Distribution
3.3 Major Manufacturers Technology Source and Market Position of Pulmonary Arterial Hypertension (PAH) Medicine
3.4 Recent Development and Expansion Plans

4 Key Figures of Major Manufacturers
4.1 Pulmonary Arterial Hypertension (PAH) Medicine Production and Capacity Analysis
4.2 Pulmonary Arterial Hypertension (PAH) Medicine Revenue Analysis
4.3 Pulmonary Arterial Hypertension (PAH) Medicine Price Analysis
4.4 Market Concentration Degree

5 Pulmonary Arterial Hypertension (PAH) Medicine Regional Market Analysis
5.1 Pulmonary Arterial Hypertension (PAH) Medicine Production by Regions
5.1.1 Global Pulmonary Arterial Hypertension (PAH) Medicine Production by Regions
5.1.2 Global Pulmonary Arterial Hypertension (PAH) Medicine Revenue by Regions
5.2 Pulmonary Arterial Hypertension (PAH) Medicine Consumption by Regions
5.3 North America Pulmonary Arterial Hypertension (PAH) Medicine Market Analysis
5.3.1 North America Pulmonary Arterial Hypertension (PAH) Medicine Production
5.3.2 North America Pulmonary Arterial Hypertension (PAH) Medicine Revenue
5.3.3 Key Manufacturers in North America
5.3.4 North America Pulmonary Arterial Hypertension (PAH) Medicine Import and Export
5.4 Europe Pulmonary Arterial Hypertension (PAH) Medicine Market Analysis
5.4.1 Europe Pulmonary Arterial Hypertension (PAH) Medicine Production
5.4.2 Europe Pulmonary Arterial Hypertension (PAH) Medicine Revenue
5.4.3 Key Manufacturers in Europe
5.4.4 Europe Pulmonary Arterial Hypertension (PAH) Medicine Import and Export
5.5 China Pulmonary Arterial Hypertension (PAH) Medicine Market Analysis
5.5.1 China Pulmonary Arterial Hypertension (PAH) Medicine Production
5.5.2 China Pulmonary Arterial Hypertension (PAH) Medicine Revenue
5.5.3 Key Manufacturers in China
5.5.4 China Pulmonary Arterial Hypertension (PAH) Medicine Import and Export
5.6 Japan Pulmonary Arterial Hypertension (PAH) Medicine Market Analysis
5.6.1 Japan Pulmonary Arterial Hypertension (PAH) Medicine Production
5.6.2 Japan Pulmonary Arterial Hypertension (PAH) Medicine Revenue
5.6.3 Key Manufacturers in Japan
5.6.4 Japan Pulmonary Arterial Hypertension (PAH) Medicine Import and Export
5.7 Southeast Asia Pulmonary Arterial Hypertension (PAH) Medicine Market Analysis
5.7.1 Southeast Asia Pulmonary Arterial Hypertension (PAH) Medicine Production
5.7.2 Southeast Asia Pulmonary Arterial Hypertension (PAH) Medicine Revenue
5.7.3 Key Manufacturers in Southeast Asia
5.7.4 Southeast Asia Pulmonary Arterial Hypertension (PAH) Medicine Import and Export
5.8 India Pulmonary Arterial Hypertension (PAH) Medicine Market Analysis
5.8.1 India Pulmonary Arterial Hypertension (PAH) Medicine Production
5.8.2 India Pulmonary Arterial Hypertension (PAH) Medicine Revenue
5.8.3 Key Manufacturers in India
5.8.4 India Pulmonary Arterial Hypertension (PAH) Medicine Import and Export

6 Pulmonary Arterial Hypertension (PAH) Medicine Segment Market Analysis (by Type)
6.1 Global Pulmonary Arterial Hypertension (PAH) Medicine Production by Type
6.2 Global Pulmonary Arterial Hypertension (PAH) Medicine Revenue by Type
6.3 Pulmonary Arterial Hypertension (PAH) Medicine Price by Type

7 Pulmonary Arterial Hypertension (PAH) Medicine Segment Market Analysis (by Application)
7.1 Global Pulmonary Arterial Hypertension (PAH) Medicine Consumption by Application
7.2 Global Pulmonary Arterial Hypertension (PAH) Medicine Consumption Market Share by Application (2014-2019)

8 Pulmonary Arterial Hypertension (PAH) Medicine Major Manufacturers Analysis
8.1 Actelion Pharmaceuticals
8.1.1 Actelion Pharmaceuticals Pulmonary Arterial Hypertension (PAH) Medicine Production Sites and Area Served
8.1.2 Actelion Pharmaceuticals Product Introduction, Application and Specification
8.1.3 Actelion Pharmaceuticals Pulmonary Arterial Hypertension (PAH) Medicine Production, Revenue, Ex-factory Price and Gross Margin (2014-2019)
8.1.4 Main Business and Markets Served
8.2 Gilead Sciences
8.2.1 Gilead Sciences Pulmonary Arterial Hypertension (PAH) Medicine Production Sites and Area Served
8.2.2 Gilead Sciences Product Introduction, Application and Specification
8.2.3 Gilead Sciences Pulmonary Arterial Hypertension (PAH) Medicine Production, Revenue, Ex-factory Price and Gross Margin (2014-2019)
8.2.4 Main Business and Markets Served
8.3 United Therapeutics Corporation
8.3.1 United Therapeutics Corporation Pulmonary Arterial Hypertension (PAH) Medicine Production Sites and Area Served
8.3.2 United Therapeutics Corporation Product Introduction, Application and Specification
8.3.3 United Therapeutics Corporation Pulmonary Arterial Hypertension (PAH) Medicine Production, Revenue, Ex-factory Price and Gross Margin (2014-2019)
8.3.4 Main Business and Markets Served
8.4 GlaxoSmithKline
8.4.1 GlaxoSmithKline Pulmonary Arterial Hypertension (PAH) Medicine Production Sites and Area Served
8.4.2 GlaxoSmithKline Product Introduction, Application and Specification
8.4.3 GlaxoSmithKline Pulmonary Arterial Hypertension (PAH) Medicine Production, Revenue, Ex-factory Price and Gross Margin (2014-2019)
8.4.4 Main Business and Markets Served
8.5 Pfizer
8.5.1 Pfizer Pulmonary Arterial Hypertension (PAH) Medicine Production Sites and Area Served
8.5.2 Pfizer Product Introduction, Application and Specification
8.5.3 Pfizer Pulmonary Arterial Hypertension (PAH) Medicine Production, Revenue, Ex-factory Price and Gross Margin (2014-2019)
8.5.4 Main Business and Markets Served
8.6 Bayer HealthCare
8.6.1 Bayer HealthCare Pulmonary Arterial Hypertension (PAH) Medicine Production Sites and Area Served
8.6.2 Bayer HealthCare Product Introduction, Application and Specification
8.6.3 Bayer HealthCare Pulmonary Arterial Hypertension (PAH) Medicine Production, Revenue, Ex-factory Price and Gross Margin (2014-2019)
8.6.4 Main Business and Markets Served
8.7 Arena Pharmaceuticals
8.7.1 Arena Pharmaceuticals Pulmonary Arterial Hypertension (PAH) Medicine Production Sites and Area Served
8.7.2 Arena Pharmaceuticals Product Introduction, Application and Specification
8.7.3 Arena Pharmaceuticals Pulmonary Arterial Hypertension (PAH) Medicine Production, Revenue, Ex-factory Price and Gross Margin (2014-2019)
8.7.4 Main Business and Markets Served

9 Development Trend of Analysis of Pulmonary Arterial Hypertension (PAH) Medicine Market
9.1 Global Pulmonary Arterial Hypertension (PAH) Medicine Market Trend Analysis
9.1.1 Global Pulmonary Arterial Hypertension (PAH) Medicine Market Size (Volume and Value) Forecast 2019-2025
9.2 Pulmonary Arterial Hypertension (PAH) Medicine Regional Market Trend
9.2.1 North America Pulmonary Arterial Hypertension (PAH) Medicine Forecast 2019-2025
9.2.2 Europe Pulmonary Arterial Hypertension (PAH) Medicine Forecast 2019-2025
9.2.3 China Pulmonary Arterial Hypertension (PAH) Medicine Forecast 2019-2025
9.2.4 Japan Pulmonary Arterial Hypertension (PAH) Medicine Forecast 2019-2025
9.2.5 Southeast Asia Pulmonary Arterial Hypertension (PAH) Medicine Forecast 2019-2025
9.2.6 India Pulmonary Arterial Hypertension (PAH) Medicine Forecast 2019-2025
9.3 Pulmonary Arterial Hypertension (PAH) Medicine Market Trend (Product Type)
9.4 Pulmonary Arterial Hypertension (PAH) Medicine Market Trend (Application)

10.1 Marketing Channel
10.1.1 Direct Marketing
10.1.2 Indirect Marketing
10.3 Pulmonary Arterial Hypertension (PAH) Medicine Customers

11 Market Dynamics
11.1 Market Trends
11.2 Opportunities
11.3 Market Drivers
11.4 Challenges
11.5 Influence Factors

12 Conclusion
13 Appendix
13.1 Methodology/Research Approach
13.1.1 Research Programs/Design
13.1.2 Market Size Estimation
13.1.3 Market Breakdown and Data Triangulation
13.2 Data Source
13.2.1 Secondary Sources
13.2.2 Primary Sources
13.3 Author List
13.4 Disclaimer

List of Tables and Figures
Figure Picture of Pulmonary Arterial Hypertension (PAH) Medicine
Table Global Pulmonary Arterial Hypertension (PAH) Medicine Production (K MT) Growth Rate Comparison by Types (2014-2025)
Figure Global Pulmonary Arterial Hypertension (PAH) Medicine Production Market Share by Types in 2018
Figure Endothelin Receptor Antagonists (ERA) Product Picture
Figure Prostacyclin And Prostacyclin Analogs Product Picture
Figure Phosphodiesterase 5 (PDE-5) Product Picture
Figure Soluble Guanylate Cyclase (SGC) Stimulators Product Picture
Table Global Pulmonary Arterial Hypertension (PAH) Medicine Consumption (K MT) Comparison by Applications (2014-2025)
Figure Global Pulmonary Arterial Hypertension (PAH) Medicine Consumption Market Share by Applications in 2018
Figure Secondary Pulmonary Hypertension (SPH)
Figure Primary Pulmonary Hypertension (PPH)
Figure Global Pulmonary Arterial Hypertension (PAH) Medicine Revenue (Million USD) (2014-2025)
Figure Global Pulmonary Arterial Hypertension (PAH) Medicine Production (K MT) (2014-2025)
Figure North America Pulmonary Arterial Hypertension (PAH) Medicine Market Size (Million USD) (2014-2025)
Figure Europe Pulmonary Arterial Hypertension (PAH) Medicine Market Size (Million USD) (2014-2025)
Figure China Pulmonary Arterial Hypertension (PAH) Medicine Market Size (Million USD) (2014-2025)
Figure Japan Pulmonary Arterial Hypertension (PAH) Medicine Market Size (Million USD) (2014-2025)
Figure Southeast Asia Pulmonary Arterial Hypertension (PAH) Medicine Market Size (Million USD) (2014-2025)
Figure India Pulmonary Arterial Hypertension (PAH) Medicine Market Size (Million USD) (2014-2025)
Table Pulmonary Arterial Hypertension (PAH) Medicine Raw Material and Suppliers
Table Manufacturing Cost Structure Analysis of Pulmonary Arterial Hypertension (PAH) Medicine in 2018
Figure Manufacturing Process Analysis of Pulmonary Arterial Hypertension (PAH) Medicine
Figure Industry Chain Structure of Pulmonary Arterial Hypertension (PAH) Medicine
Table Capacity and Commercial Production Date of Key Manufacturers
Table Global Pulmonary Arterial Hypertension (PAH) Medicine Manufacturing Plants Distribution
Table Pulmonary Arterial Hypertension (PAH) Medicine Major Manufacturers Technology Source and Market Position
Table Recent Development and Expansion Plans in Future
Table Pulmonary Arterial Hypertension (PAH) Medicine Capacity (K MT) of Major Manufacturers (2014-2019)
Table Pulmonary Arterial Hypertension (PAH) Medicine Production (K MT) of Major Manufacturers (2014-2019)
Table Pulmonary Arterial Hypertension (PAH) Medicine Production Market Share of Major Manufacturers (2014-2019)
Figure Pulmonary Arterial Hypertension (PAH) Medicine Production Share by Manufacturers in 2018
Table Pulmonary Arterial Hypertension (PAH) Medicine Revenue (Million US$) of Major Manufacturers (2014-2019)
Table Pulmonary Arterial Hypertension (PAH) Medicine Revenue Market Share of Major Manufacturers (2014-2019)
Figure Pulmonary Arterial Hypertension (PAH) Medicine Revenue Share by Manufacturers in 2018
Table Pulmonary Arterial Hypertension (PAH) Medicine Average Price (USD/MT) of Major Manufacturers (2014-2019)
Table Global Manufacturers Market Concentration Ratio (CR5 and HHI)
Table Global Pulmonary Arterial Hypertension (PAH) Medicine Production by Regions 2014-2019 (K MT)
Table Global Pulmonary Arterial Hypertension (PAH) Medicine Production Market Share by Regions 2014-2019
Figure Global Pulmonary Arterial Hypertension (PAH) Medicine Production Market Share by Regions in 2018
Table Global Pulmonary Arterial Hypertension (PAH) Medicine Revenue by Regions 2014-2019 (Million USD)
Table Global Pulmonary Arterial Hypertension (PAH) Medicine Revenue Market Share by Regions 2014-2019
Figure Global Pulmonary Arterial Hypertension (PAH) Medicine Revenue Market Share by Regions in 2018
Table Global Pulmonary Arterial Hypertension (PAH) Medicine Consumption by Regions 2014-2019 (K MT)
Table Global Pulmonary Arterial Hypertension (PAH) Medicine Consumption Market Share by Regions 2014-2019
Figure North America Pulmonary Arterial Hypertension (PAH) Medicine Production Growth Rate 2014-2019 (K MT)
Figure North America Pulmonary Arterial Hypertension (PAH) Medicine Revenue Growth Rate 2014-2019 (Million USD)
Table North America Pulmonary Arterial Hypertension (PAH) Medicine Production, Consumption Import and Export (K MT)
Figure Europe Pulmonary Arterial Hypertension (PAH) Medicine Production Growth Rate 2014-2019 (K MT)
Figure Europe Pulmonary Arterial Hypertension (PAH) Medicine Revenue Growth Rate 2014-2019 (Million USD)
Table Europe Pulmonary Arterial Hypertension (PAH) Medicine Production, Consumption Import and Export (K MT)
Figure China Pulmonary Arterial Hypertension (PAH) Medicine Production Growth Rate 2014-2019 (K MT)
Figure China Pulmonary Arterial Hypertension (PAH) Medicine Revenue Growth Rate 2014-2019 (Million USD)
Table China Pulmonary Arterial Hypertension (PAH) Medicine Production, Consumption Import and Export (K MT)
Figure Japan Pulmonary Arterial Hypertension (PAH) Medicine Production Growth Rate 2014-2019 (K MT)
Figure Japan Pulmonary Arterial Hypertension (PAH) Medicine Revenue Growth Rate 2014-2019 (Million USD)
Table Japan Pulmonary Arterial Hypertension (PAH) Medicine Production, Consumption Import and Export (K MT)
Figure Southeast Asia Pulmonary Arterial Hypertension (PAH) Medicine Production Growth Rate 2014-2019 (K MT)
Figure Southeast Asia Pulmonary Arterial Hypertension (PAH) Medicine Revenue Growth Rate 2014-2019 (Million USD)
Table Southeast Asia Pulmonary Arterial Hypertension (PAH) Medicine Production, Consumption Import and Export (K MT)
Figure India Pulmonary Arterial Hypertension (PAH) Medicine Production Growth Rate 2014-2019 (K MT)
Figure India Pulmonary Arterial Hypertension (PAH) Medicine Revenue Growth Rate 2014-2019 (Million USD)
Table India Pulmonary Arterial Hypertension (PAH) Medicine Production, Consumption Import and Export (K MT)
Figure Global Consumption Pulmonary Arterial Hypertension (PAH) Medicine Market Share by Application (2014-2019)
Figure Global Value (Consumption) Pulmonary Arterial Hypertension (PAH) Medicine Market Share by Application (2014-2019)
Table Actelion Pharmaceuticals Pulmonary Arterial Hypertension (PAH) Medicine Production Sites and Area Served
Table Actelion Pharmaceuticals Pulmonary Arterial Hypertension (PAH) Medicine Product Introduction, Application and Specification
Table Actelion Pharmaceuticals Pulmonary Arterial Hypertension (PAH) Medicine Production (K MT), Revenue (Million USD), Ex-factory Price (USD/MT) and Gross Margin (2014-2019)
Table Actelion Pharmaceuticals Pulmonary Arterial Hypertension (PAH) Medicine Production Growth Rate (2014-2019)
Table Actelion Pharmaceuticals Pulmonary Arterial Hypertension (PAH) Medicine Production Market Share (2014-2019)
Figure Actelion Pharmaceuticals Pulmonary Arterial Hypertension (PAH) Medicine Revenue Market Share (2014-2019)
Table Actelion Pharmaceuticals Pulmonary Arterial Hypertension (PAH) Medicine Main Business and Markets Served
Table Gilead Sciences Pulmonary Arterial Hypertension (PAH) Medicine Production Sites and Area Served
Table Gilead Sciences Pulmonary Arterial Hypertension (PAH) Medicine Product Introduction, Application and Specification
Table Gilead Sciences Pulmonary Arterial Hypertension (PAH) Medicine Production (K MT), Revenue (Million USD), Ex-factory Price (USD/MT) and Gross Margin (2014-2019)
Table Gilead Sciences Pulmonary Arterial Hypertension (PAH) Medicine Production Growth Rate (2014-2019)
Table Gilead Sciences Pulmonary Arterial Hypertension (PAH) Medicine Production Market Share (2014-2019)
Figure Gilead Sciences Pulmonary Arterial Hypertension (PAH) Medicine Revenue Market Share (2014-2019)
Table Gilead Sciences Pulmonary Arterial Hypertension (PAH) Medicine Main Business and Markets Served
Table United Therapeutics Corporation Pulmonary Arterial Hypertension (PAH) Medicine Production Sites and Area Served
Table United Therapeutics Corporation Pulmonary Arterial Hypertension (PAH) Medicine Product Introduction, Application and Specification
Table United Therapeutics Corporation Pulmonary Arterial Hypertension (PAH) Medicine Production (K MT), Revenue (Million USD), Ex-factory Price (USD/MT) and Gross Margin (2014-2019)
Table United Therapeutics Corporation Pulmonary Arterial Hypertension (PAH) Medicine Production Growth Rate (2014-2019)
Table United Therapeutics Corporation Pulmonary Arterial Hypertension (PAH) Medicine Production Market Share (2014-2019)
Figure United Therapeutics Corporation Pulmonary Arterial Hypertension (PAH) Medicine Revenue Market Share (2014-2019)
Table United Therapeutics Corporation Pulmonary Arterial Hypertension (PAH) Medicine Main Business and Markets Served
Table GlaxoSmithKline Pulmonary Arterial Hypertension (PAH) Medicine Production Sites and Area Served
Table GlaxoSmithKline Pulmonary Arterial Hypertension (PAH) Medicine Product Introduction, Application and Specification
Table GlaxoSmithKline Pulmonary Arterial Hypertension (PAH) Medicine Production (K MT), Revenue (Million USD), Ex-factory Price (USD/MT) and Gross Margin (2014-2019)
Table GlaxoSmithKline Pulmonary Arterial Hypertension (PAH) Medicine Production Growth Rate (2014-2019)
Table GlaxoSmithKline Pulmonary Arterial Hypertension (PAH) Medicine Production Market Share (2014-2019)
Figure GlaxoSmithKline Pulmonary Arterial Hypertension (PAH) Medicine Revenue Market Share (2014-2019)
Table GlaxoSmithKline Pulmonary Arterial Hypertension (PAH) Medicine Main Business and Markets Served
Table Pfizer Pulmonary Arterial Hypertension (PAH) Medicine Production Sites and Area Served
Table Pfizer Pulmonary Arterial Hypertension (PAH) Medicine Product Introduction, Application and Specification
Table Pfizer Pulmonary Arterial Hypertension (PAH) Medicine Production (K MT), Revenue (Million USD), Ex-factory Price (USD/MT) and Gross Margin (2014-2019)
Table Pfizer Pulmonary Arterial Hypertension (PAH) Medicine Production Growth Rate (2014-2019)
Table Pfizer Pulmonary Arterial Hypertension (PAH) Medicine Production Market Share (2014-2019)
Figure Pfizer Pulmonary Arterial Hypertension (PAH) Medicine Revenue Market Share (2014-2019)
Table Pfizer Pulmonary Arterial Hypertension (PAH) Medicine Main Business and Markets Served
Table Bayer HealthCare Pulmonary Arterial Hypertension (PAH) Medicine Production Sites and Area Served
Table Bayer HealthCare Pulmonary Arterial Hypertension (PAH) Medicine Product Introduction, Application and Specification
Table Bayer HealthCare Pulmonary Arterial Hypertension (PAH) Medicine Production (K MT), Revenue (Million USD), Ex-factory Price (USD/MT) and Gross Margin (2014-2019)
Table Bayer HealthCare Pulmonary Arterial Hypertension (PAH) Medicine Production Growth Rate (2014-2019)
Table Bayer HealthCare Pulmonary Arterial Hypertension (PAH) Medicine Production Market Share (2014-2019)
Figure Bayer HealthCare Pulmonary Arterial Hypertension (PAH) Medicine Revenue Market Share (2014-2019)
Table Bayer HealthCare Pulmonary Arterial Hypertension (PAH) Medicine Main Business and Markets Served
Table Arena Pharmaceuticals Pulmonary Arterial Hypertension (PAH) Medicine Production Sites and Area Served
Table Arena Pharmaceuticals Pulmonary Arterial Hypertension (PAH) Medicine Product Introduction, Application and Specification
Table Arena Pharmaceuticals Pulmonary Arterial Hypertension (PAH) Medicine Production (K MT), Revenue (Million USD), Ex-factory Price (USD/MT) and Gross Margin (2014-2019)
Table Arena Pharmaceuticals Pulmonary Arterial Hypertension (PAH) Medicine Production Growth Rate (2014-2019)
Table Arena Pharmaceuticals Pulmonary Arterial Hypertension (PAH) Medicine Production Market Share (2014-2019)
Figure Arena Pharmaceuticals Pulmonary Arterial Hypertension (PAH) Medicine Revenue Market Share (2014-2019)
Table Arena Pharmaceuticals Pulmonary Arterial Hypertension (PAH) Medicine Main Business and Markets Served
Figure Global Pulmonary Arterial Hypertension (PAH) Medicine Production (K MT) Growth Rate Forecast 2019-2025
Figure Global Pulmonary Arterial Hypertension (PAH) Medicine Revenue (Million USD) Growth Rate Forecast 2019-2025
Figure Global Pulmonary Arterial Hypertension (PAH) Medicine Sales Price (USD/MT) Forecast 2019-2025
Figure North America Pulmonary Arterial Hypertension (PAH) Medicine Production Growth Rate Forecast 2019-2025 (K MT)
Figure North America Pulmonary Arterial Hypertension (PAH) Medicine Revenue Growth Rate Forecast 2019-2025 (Million USD)
Figure Europe Pulmonary Arterial Hypertension (PAH) Medicine Production Growth Rate Forecast 2019-2025 (K MT)
Figure Europe Pulmonary Arterial Hypertension (PAH) Medicine Revenue Growth Rate Forecast 2019-2025 (Million USD)
Figure China Pulmonary Arterial Hypertension (PAH) Medicine Production Growth Rate Forecast 2019-2025 (K MT)
Figure China Pulmonary Arterial Hypertension (PAH) Medicine Revenue Growth Rate Forecast 2019-2025 (Million USD)
Figure Japan Pulmonary Arterial Hypertension (PAH) Medicine Production Growth Rate Forecast 2019-2025 (K MT)
Figure Japan Pulmonary Arterial Hypertension (PAH) Medicine Revenue Growth Rate Forecast 2019-2025 (Million USD)
Figure Southeast Asia Pulmonary Arterial Hypertension (PAH) Medicine Production Growth Rate Forecast 2019-2025 (K MT)
Figure Southeast Asia Pulmonary Arterial Hypertension (PAH) Medicine Revenue Growth Rate Forecast 2019-2025 (Million USD)
Figure India Pulmonary Arterial Hypertension (PAH) Medicine Production Growth Rate Forecast 2019-2025 (K MT)
Figure India Pulmonary Arterial Hypertension (PAH) Medicine Revenue Growth Rate Forecast 2019-2025 (Million USD)
Table Global Production (K MT) of Pulmonary Arterial Hypertension (PAH) Medicine by Type (2019-2025)
Table Global Consumption (K MT) of Pulmonary Arterial Hypertension (PAH) Medicine by Application (2019-2025)
Table Pulmonary Arterial Hypertension (PAH) Medicine Distributors List
Table Pulmonary Arterial Hypertension (PAH) Medicine Customers List
Table Market Key Trends
Table Key Opportunities
Table Market Key Drivers
Table Key Challenges
Table Key Influence Factors
Table Research Programs/Design for This Report
Figure Bottom-up and Top-down Approaches for This Report
Figure Data Triangulation
Table Key Data Information from Secondary Sources
Table Key Data Information from Primary Sources


【掲載企業】

Actelion Pharmaceuticals、Gilead Sciences、United Therapeutics Corporation、GlaxoSmithKline、Pfizer、Bayer HealthCare、Arena Pharmaceuticals、

★調査レポート[世界の肺動脈高血圧症（PAH）治療薬市場 2019年] (コード：DATA909X13888)販売に関する免責事項を必ずご確認ください。
★調査レポート[世界の肺動脈高血圧症（PAH）治療薬市場 2019年]についてメールでお問い合わせ
◆関連市場調査レポート◆
  • 世界の急性呼吸窮迫症候群(ARDS)治療薬市場 2019年
    DATA909X02949 / QYResearch / 2019年11月15日 / ※本調査レポートは、急性呼吸窮迫症候群(ARDS)治療薬の世界市場概要、製造コスト分析、開発・製造工場分析、主要メーカー分析、地域別分析情報、市場規模予測データ、マーケティングチャネル、流通業者リスト、顧客リストなどが含まれています。種類別には、メチルプレドニゾロン、ヒドロコルチゾン、注射用子牛肺サーファクタント、その他に、用途別には、入院患者、外来患者にセグメント区分し、急性呼吸窮迫症候群(ARDS)治療薬の世界市場を分析しました。 ・エグゼクティブ・サマリー ・急性呼吸窮迫症候群(ARDS)治療薬の世界市場概要 ・急性呼吸窮迫症候群(ARDS)治療薬の製造コスト構成分析 ・急性呼吸窮迫症候群(ARDS)治療薬の開発・製造工場分析 ・主要メーカーの主な指標（生産能力、売上、価格分析） ・急性呼吸窮迫症候群(ARDS)治療薬の地域別分析（生産、売上、主要メーカー、輸出・輸入） （北米、ヨーロッパ、中国、日本国内、東南アジア、インド） ・急性呼吸窮迫症候群(ARDS)治療薬のセグメント分析（種類別） （メチルプレドニゾロン、ヒドロコルチゾン、注射用子牛肺サーファクタント、その他）...The global Acute Respiratory Distress Syndrome Therapeutics market was valued at million US$ in 2018 and will reach million US$ by the end of 2025, growing at a CAGR of during 2019-2025. This report focuses on Acute Respiratory Distress Syndrome Therapeutics volume and value at global level, regional level and company level. From a global perspective, this report represents overall Acute Respiratory Distress Syndrome Therapeutics market size by analyzing historical data and future prospect. Regionally, this report categorizes the production, apparent consumption, export and import of Acute Respiratory Distress Syndrome Therapeutics in North America, Europe, China, Japan, Southeast Asia and...
  • 世界の多嚢胞性卵巣症候群（PCOS）治療薬市場 2019年
    DATA909X13285 / QYResearch / 2019年11月20日 / ※本調査レポートは、多嚢胞性卵巣症候群（PCOS）治療薬の世界市場概要、製造コスト分析、開発・製造工場分析、主要メーカー分析、地域別分析情報、市場規模予測データ、マーケティングチャネル、流通業者リスト、顧客リストなどが含まれています。種類別には、経口避妊薬、抗炎症薬、インスリン抵抗性改善薬、抗高血圧薬、抗肥満薬に、用途別には、病院、クリニックにセグメント区分し、多嚢胞性卵巣症候群（PCOS）治療薬の世界市場を分析しました。 ・エグゼクティブ・サマリー ・多嚢胞性卵巣症候群（PCOS）治療薬の世界市場概要 ・多嚢胞性卵巣症候群（PCOS）治療薬の製造コスト構成分析 ・多嚢胞性卵巣症候群（PCOS）治療薬の開発・製造工場分析 ・主要メーカーの主な指標（生産能力、売上、価格分析） ・多嚢胞性卵巣症候群（PCOS）治療薬の地域別分析（生産、売上、主要メーカー、輸出・輸入） （北米、ヨーロッパ、中国、日本国内、東南アジア、インド） ・多嚢胞性卵巣症候群（PCOS）治療薬のセグメント分析（種類別） （経口避妊薬、抗炎症薬、インスリン抵抗性改善薬、抗高血圧薬、抗肥満薬）...The global Polycystic Ovary Syndrome (PCOS) Drugs market was valued at million US$ in 2018 and will reach million US$ by the end of 2025, growing at a CAGR of during 2019-2025. This report focuses on Polycystic Ovary Syndrome (PCOS) Drugs volume and value at global level, regional level and company level. From a global perspective, this report represents overall Polycystic Ovary Syndrome (PCOS) Drugs market size by analyzing historical data and future prospect. Regionally, this report categorizes the production, apparent consumption, export and import of Polycystic Ovary Syndrome (PCOS) Drugs in North America, Europe, China, Japan, Southeast Asia and...
  • 世界の急性心不全(AHF)治療薬市場 2019年
    DATA909X02947 / QYResearch / 2019年11月15日 / ※本調査レポートは、急性心不全(AHF)治療薬の世界市場概要、製造コスト分析、開発・製造工場分析、主要メーカー分析、地域別分析情報、市場規模予測データ、マーケティングチャネル、流通業者リスト、顧客リストなどが含まれています。種類別には、β遮断薬、カルシウム拮抗薬、強心配糖体、利尿薬、モルヒネ、血管拡張薬/硝酸塩、その他に、用途別には、病院、クリニック、ホームケアにセグメント区分し、急性心不全(AHF)治療薬の世界市場を分析しました。 ・エグゼクティブ・サマリー ・急性心不全(AHF)治療薬の世界市場概要 ・急性心不全(AHF)治療薬の製造コスト構成分析 ・急性心不全(AHF)治療薬の開発・製造工場分析 ・主要メーカーの主な指標（生産能力、売上、価格分析） ・急性心不全(AHF)治療薬の地域別分析（生産、売上、主要メーカー、輸出・輸入） （北米、ヨーロッパ、中国、日本国内、東南アジア、インド） ・急性心不全(AHF)治療薬のセグメント分析（種類別） （β遮断薬、カルシウム拮抗薬、強心配糖体、利尿薬、モルヒネ、血管拡張薬/硝酸塩、その他）...The global Acute Heart Failure (AHF) Therapeutics market was valued at million US$ in 2018 and will reach million US$ by the end of 2025, growing at a CAGR of during 2019-2025. This report focuses on Acute Heart Failure (AHF) Therapeutics volume and value at global level, regional level and company level. From a global perspective, this report represents overall Acute Heart Failure (AHF) Therapeutics market size by analyzing historical data and future prospect. Regionally, this report categorizes the production, apparent consumption, export and import of Acute Heart Failure (AHF) Therapeutics in North America, Europe, China, Japan, Southeast Asia and...
  • 世界の呼吸器合胞体ウイルス（RSV）治療薬市場 2019年
    DATA909X14332 / QYResearch / 2019年11月20日 / ※本調査レポートは、呼吸器合胞体ウイルス（RSV）治療薬の世界市場概要、製造コスト分析、開発・製造工場分析、主要メーカー分析、地域別分析情報、市場規模予測データ、マーケティングチャネル、流通業者リスト、顧客リストなどが含まれています。種類別には、パリビズマブ、リバビリン、その他に、用途別には、病院薬局、ドラッグストア、小売薬局、その他にセグメント区分し、呼吸器合胞体ウイルス（RSV）治療薬の世界市場を分析しました。 ・エグゼクティブ・サマリー ・呼吸器合胞体ウイルス（RSV）治療薬の世界市場概要 ・呼吸器合胞体ウイルス（RSV）治療薬の製造コスト構成分析 ・呼吸器合胞体ウイルス（RSV）治療薬の開発・製造工場分析 ・主要メーカーの主な指標（生産能力、売上、価格分析） ・呼吸器合胞体ウイルス（RSV）治療薬の地域別分析（生産、売上、主要メーカー、輸出・輸入） （北米、ヨーロッパ、中国、日本国内、東南アジア、インド） ・呼吸器合胞体ウイルス（RSV）治療薬のセグメント分析（種類別） （パリビズマブ、リバビリン、その他）...The global Respiratory Syncytial Virus (RSV) Therapeutics market was valued at million US$ in 2018 and will reach million US$ by the end of 2025, growing at a CAGR of during 2019-2025. This report focuses on Respiratory Syncytial Virus (RSV) Therapeutics volume and value at global level, regional level and company level. From a global perspective, this report represents overall Respiratory Syncytial Virus (RSV) Therapeutics market size by analyzing historical data and future prospect. Regionally, this report categorizes the production, apparent consumption, export and import of Respiratory Syncytial Virus (RSV) Therapeutics in North America, Europe, China, Japan, Southeast Asia and...
  • 世界の多発性硬化症（MS）治療薬市場 2019年
    DATA909X11757 / QYResearch / 2019年11月20日 / ※本調査レポートは、多発性硬化症（MS）治療薬の世界市場概要、製造コスト分析、開発・製造工場分析、主要メーカー分析、地域別分析情報、市場規模予測データ、マーケティングチャネル、流通業者リスト、顧客リストなどが含まれています。種類別には、コパキソン（酢酸グラチラマー、共重合体1）、ノバントロン（ミトキサントロン）、ギレニア（フィンゴリモド、Fty720）、オーバジオ（テリフルノミド）、テクフィデラ（フマル酸ジメチル）、フィラテグラス（Sb683699、T-0047）、シポニモド（Baf312）、その他に、用途別には、RRMS、SPMS、PPMS、PRMSにセグメント区分し、多発性硬化症（MS）治療薬の世界市場を分析しました。 ・エグゼクティブ・サマリー ・多発性硬化症（MS）治療薬の世界市場概要 ・多発性硬化症（MS）治療薬の製造コスト構成分析 ・多発性硬化症（MS）治療薬の開発・製造工場分析 ・主要メーカーの主な指標（生産能力、売上、価格分析） ・多発性硬化症（MS）治療薬の地域別分析（生産、売上、主要メーカー、輸出・輸入） （北米、ヨーロッパ、中国、日本国内、東南アジア、インド） ・多発性硬化症（MS）治療薬のセグメント分析（種類別） （コパキソン（酢酸グラチラマー、共重合体1）、ノバントロン（ミトキサントロン）、ギレニア（フィンゴリモド、Fty720）、オーバジオ（テリフルノミド）、テクフィデラ（フマル酸ジメチル）、フィラテグラス（Sb683699、T-0047）、シポニモド（Baf312）、その他）...The global Multiple Sclerosis (MS) Drugs market was valued at million US$ in 2018 and will reach million US$ by the end of 2025, growing at a CAGR of during 2019-2025. This report focuses on Multiple Sclerosis (MS) Drugs volume and value at global level, regional level and company level. From a global perspective, this report represents overall Multiple Sclerosis (MS) Drugs market size by analyzing historical data and future prospect. Regionally, this report categorizes the production, apparent consumption, export and import of Multiple Sclerosis (MS) Drugs in North America, Europe, China, Japan, Southeast Asia and India. For each manufacturer...
  • 世界の骨髄異形成症候群（MDS）治療薬市場 2019年
    DATA909X11785 / QYResearch / 2019年11月20日 / ※本調査レポートは、骨髄異形成症候群（MDS）治療薬の世界市場概要、製造コスト分析、開発・製造工場分析、主要メーカー分析、地域別分析情報、市場規模予測データ、マーケティングチャネル、流通業者リスト、顧客リストなどが含まれています。種類別には、アザシチジン、レナリドマイド、デシタビン、デフェラシロクス、その他に、用途別には、入院患者、外来患者にセグメント区分し、骨髄異形成症候群（MDS）治療薬の世界市場を分析しました。 ・エグゼクティブ・サマリー ・骨髄異形成症候群（MDS）治療薬の世界市場概要 ・骨髄異形成症候群（MDS）治療薬の製造コスト構成分析 ・骨髄異形成症候群（MDS）治療薬の開発・製造工場分析 ・主要メーカーの主な指標（生産能力、売上、価格分析） ・骨髄異形成症候群（MDS）治療薬の地域別分析（生産、売上、主要メーカー、輸出・輸入） （北米、ヨーロッパ、中国、日本国内、東南アジア、インド） ・骨髄異形成症候群（MDS）治療薬のセグメント分析（種類別） （アザシチジン、レナリドマイド、デシタビン、デフェラシロクス、その他）...The global Myelodysplastic Syndrome (MDS) Therapeutics market was valued at million US$ in 2018 and will reach million US$ by the end of 2025, growing at a CAGR of during 2019-2025. This report focuses on Myelodysplastic Syndrome (MDS) Therapeutics volume and value at global level, regional level and company level. From a global perspective, this report represents overall Myelodysplastic Syndrome (MDS) Therapeutics market size by analyzing historical data and future prospect. Regionally, this report categorizes the production, apparent consumption, export and import of Myelodysplastic Syndrome (MDS) Therapeutics in North America, Europe, China, Japan, Southeast Asia and India. For each manufacturer...

    • ◆H&Iグローバルリサーチのお客様（例）◆